Sarepta Therapeutics has found itself at the center of controversy after announcing significant layoffs, acknowledging a patient death related to one of its gene therapies, and refusing FDA orders to suspend shipments of its marketed product Elevidys. The company’s stock price has plummeted 30% in the past week alone.
The rapid decline is a stark contrast to Sarepta’s initial promise as a leading biotech firm. However, this situation highlights the risks associated with lowering regulatory barriers for new medicines and the incentives it creates for biotechnology companies. It serves as a cautionary tale of what not to do when developing a breakthrough product, emphasizing the importance of effective communication and responsible business practices.
Source: https://www.statnews.com/2025/07/21/sarepta-therapeutics-elevydis-duchenne-fda-lessons